DEXUVE Trademark

Trademark Overview


On Thursday, May 16, 2019, a trademark application was filed for DEXUVE with the United States Patent and Trademark Office. The USPTO has given the DEXUVE trademark a serial number of 79261531. The federal status of this trademark filing is REGISTERED as of Tuesday, December 15, 2020. This trademark is owned by Glaxo Group Limited. The DEXUVE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
dexuve

General Information


Serial Number79261531
Word MarkDEXUVE
Filing DateThursday, May 16, 2019
Status700 - REGISTERED
Status DateTuesday, December 15, 2020
Registration Number6218841
Registration DateTuesday, December 15, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 29, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, June 28, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressGB

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressGB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressGB

Trademark Events


Event DateEvent Description
Sunday, July 23, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Monday, April 12, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, March 19, 2021FINAL DISPOSITION NOTICE SENT TO IB
Friday, March 19, 2021FINAL DISPOSITION PROCESSED
Monday, March 15, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, December 19, 2020NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, December 15, 2020REGISTERED-PRINCIPAL REGISTER
Wednesday, December 2, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, December 2, 2020NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, September 29, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 29, 2020PUBLISHED FOR OPPOSITION
Wednesday, September 9, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 26, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 25, 2020SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Thursday, August 6, 2020ASSIGNED TO LIE
Thursday, January 16, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, January 16, 2020LETTER OF SUSPENSION E-MAILED
Thursday, January 16, 2020SUSPENSION LETTER WRITTEN
Wednesday, January 15, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 15, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 15, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 16, 2019REFUSAL PROCESSED BY IB
Saturday, July 27, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, July 27, 2019REFUSAL PROCESSED BY MPU
Saturday, July 6, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 5, 2019NON-FINAL ACTION WRITTEN
Thursday, July 4, 2019ASSIGNED TO EXAMINER
Tuesday, July 2, 2019APPLICATION FILING RECEIPT MAILED
Friday, June 28, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 27, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB